Pathophysiology of portal hypertension

被引:30
|
作者
Gupta, TK
Chen, L
Groszmann, RJ
机构
[1] VET ADM MED CTR,HEPAT HEMODYNAM LAB,W HAVEN,CT 06516
[2] YALE UNIV,SCH MED,NEW HAVEN,CT 06510
[3] BRIDGEPORT HOSP,BRIDGEPORT,CT 06610
来源
BAILLIERES CLINICAL GASTROENTEROLOGY | 1997年 / 11卷 / 02期
关键词
portal hypertension; porto-systemic collaterals; hyperdynamic circulation; vasodilators; vasoconstrictors; oesophageal varices; variceal haemorrhage; plasma volume; intrahepatic resistance; pharmacotherapy;
D O I
10.1016/S0950-3528(97)90036-1
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Portal hypertension is a common clinical syndrome associated with chronic liver diseases and is characterized by a pathological increase in portal pressure. Increase in portal pressure is because of an increase in vascular resistance and an elevated portal blood Bow. The site of increased intrahepatic resistance is variable and is dependent on the disease process. The site of obstruction may be: pre-hepatic, hepatic, and/or post-hepatic. In addition, part of the increased intrahepatic resistance is because of increased vascular tone. Another important factor contributing to increased portal pressure is elevated blood how Peripheral vasodilatation initiates the classical profile of decreased systemic resistance, expanded plasma volume, elevated splanchnic blood flow and elevated cardiac index. The elevated portal pressure leads to formation of portosystemic collaterals and oesophageal varices. Pharmacotherapy for portal hypertension is aimed at reducing both intrahepatic vascular tone and elevated splanchnic blood flow.
引用
收藏
页码:203 / 219
页数:17
相关论文
共 50 条
  • [21] Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension
    Mejias, Marc
    Garcia-Pras, Ester
    Gallego, Javier
    Mendez, Raul
    Bosch, Jaime
    Fernandez, Mercedes
    JOURNAL OF HEPATOLOGY, 2010, 52 (04) : 529 - 539
  • [22] Pathogenesis of portal hypertension
    Montaño-Loza, A
    Meza-Junco, J
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2005, 57 (04): : 596 - 607
  • [23] Idiopathic portal hypertension
    Sarin, SK
    Aggarwal, SR
    DIGESTION, 1998, 59 (04) : 420 - 423
  • [24] Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction
    Engelmann, Cornelius
    Claria, Joan
    Szabo, Gyongyi
    Bosch, Jaume
    Bernardi, Mauro
    JOURNAL OF HEPATOLOGY, 2021, 75 : S49 - S66
  • [25] Aspects of pathogenetc pharmacotherapy for portal hypertension in liver cirrhosis
    Garbuzenko, D. V.
    TERAPEVTICHESKII ARKHIV, 2016, 88 (02) : 101 - 108
  • [26] PATHOGENESIS OF PORTAL-HYPERTENSION
    HOLSTEGE, A
    ANDUS, T
    GROSS, V
    KOLLINGER, M
    SCHOLMERICH, J
    MEDIZINISCHE WELT, 1993, 44 (07): : 431 - 438
  • [27] Animal models of portal hypertension
    Koenigshofer, P.
    Brusilovskaya, K.
    Schwabl, P.
    Reiberger, T.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2019, 1865 (05): : 1019 - 1030
  • [28] Portal hypertension: state of the art
    Gatta, A
    Sacerdoti, D
    Bolognesi, M
    Merkel, C
    ITALIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1999, 31 (04): : 326 - 345
  • [29] Portal hypertension and oesophageal varices
    Rodeck, B
    MONATSSCHRIFT KINDERHEILKUNDE, 2002, 150 (01) : 40 - +
  • [30] Diagnosis and monitoring of portal hypertension
    de Franchis, R.
    Dell'Era, A.
    Primignani, A.
    DIGESTIVE AND LIVER DISEASE, 2008, 40 (05) : 312 - 317